TROPION-Lung05
The study that got Datroway approved for EGFR-mutant lung cancer after other treatments fail.
137 patients (78 EGFR-mutant). ORR 35.8% overall, 43.6% in EGFR-mutant; median DOR 7.0 months. Pooled with TROPION-Lung01 EGFR-mutant patients (ORR 45%) to support accelerated approval in June 2025.
- 35.8 vs 43.6 out of 100 had their tumour shrink with Datopotamab deruxtecan, all compared with EGFR-mutant subgroup; 7.8 fewer per 100.
- On this measure the first group did worse, not better.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Actionable-genomic-alteration NSCLC after targeted therapy and platinum: datopotamab deruxtecan single arm. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
137 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rate (BICR)primary | Datopotamab deruxtecan, all | 137 | 35.8% | — | — | link |
| EGFR-mutant subgroup | 78 | 43.6% |
Pages like this
not linked directly; found by shared links- PersonBenjamin Besse
Shares TROPION-Lung01, Datopotamab deruxtecan, Non-small-cell lung cancer.
- TrialLAURA
Shares EGFR, Non-small-cell lung cancer.
- ProductDacomitinib
Shares EGFR, Non-small-cell lung cancer.
- PersonMatthew Meyerson
Shares EGFR, Non-small-cell lung cancer.
- PersonDaniel A. Haber
Shares EGFR, Non-small-cell lung cancer.
- PersonThomas J. Lynch Jr.
Shares EGFR, Non-small-cell lung cancer.
- PairingTROP2 PET → TROP2 ADC selection
Shares Datopotamab deruxtecan, TROP2, Non-small-cell lung cancer.
- PersonJean-Charles Soria
Shares EGFR, Non-small-cell lung cancer.